By InvitationPhase 2

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

United States, United Kingdom500 participantsStarted 2018-08-02

Plain-language summary

Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.

Age range1 Year

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Patients must have received an AUTO CAR T cell therapy on a clinical treatment study.
✓. Patients must have provided informed consent for long-term follow-up study prior to participation.
✓. Patients must be able to comply with the study requirements.

Incidence of Serious Adverse Events (SAE), new malignancies & adverse events of special interest (AESI) related to AUTO CAR T cell therapy

Timeframe: For up to 15 years

NCT IDNCT03628612

SponsorAutolus Limited

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2043-07